The presentation will begin after in-person meals are served (an estimated 15-30 minute delay). Thank you for your patience.
Individuals with schizophrenia have a life expectancy that is, on average, twenty years lower than the general population. One potential explanation is the increased prevalence of metabolic issues, including obesity, hypertension, hypercholesterolemia, and diabetes that is found amongst individuals with schizophrenia. Data suggest that clinicians are not currently managing or recognizing metabolic side effects of antipsychotics adequately, in part due to a lack of confidence and/or knowledge with respect to proper management. In addition, approved treatments are only just recently available and may not be well known or confidently added into standard clinical practice. Continuing education to address these gaps in clinician understanding is vital towards improving the treatment outcomes of patients with antipsychotic-related metabolic side effects. In this program, Dr. Jonathan Meyer will discuss the most current research findings on how to effectively manage adverse metabolic effects associated with antipsychotic use, not only in schizophrenia but also the many other mental health disorders in which antipsychotics are often employed.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
